<SEC-DOCUMENT>0001193125-25-245275.txt : 20251021
<SEC-HEADER>0001193125-25-245275.hdr.sgml : 20251021
<ACCEPTANCE-DATETIME>20251021170057
ACCESSION NUMBER:		0001193125-25-245275
CONFORMED SUBMISSION TYPE:	DEFA14A
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20251021
DATE AS OF CHANGE:		20251021

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			HOLOGIC INC
		CENTRAL INDEX KEY:			0000859737
		STANDARD INDUSTRIAL CLASSIFICATION:	X-RAY APPARATUS & TUBES & RELATED IRRADIATION APPARATUS [3844]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		EIN:				042902449
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0928

	FILING VALUES:
		FORM TYPE:		DEFA14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36214
		FILM NUMBER:		251407788

	BUSINESS ADDRESS:	
		STREET 1:		250 CAMPUS DRIVE
		CITY:			MARLBOROUGH
		STATE:			MA
		ZIP:			01752
		BUSINESS PHONE:		5082632900

	MAIL ADDRESS:	
		STREET 1:		250 CAMPUS DRIVE
		CITY:			MARLBOROUGH
		STATE:			MA
		ZIP:			01752
</SEC-HEADER>
<DOCUMENT>
<TYPE>DEFA14A
<SEQUENCE>1
<FILENAME>d54832ddefa14a.htm
<DESCRIPTION>DEFA14A
<TEXT>
<HTML><HEAD>
<TITLE>DEFA14A</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
<DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;
</DIV><DIV STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE 14A </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Proxy
Statement Pursuant to Section&nbsp;14(a) of the </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Securities Exchange Act of 1934 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>(Amendment No. &#8195;) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Filed by the Registrant &#9745; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Filed by a Party other than
the Registrant &#9744; </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Preliminary Proxy Statement </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B></B>&#9744;<B></B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Confidential, for Use of the Commission Only (as permitted by Rule
<FONT STYLE="white-space:nowrap">14a-6(e)(2))</FONT> </B></P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Definitive Proxy Statement </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Definitive Additional Materials </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9745;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Soliciting Material Pursuant to <FONT STYLE="white-space:nowrap">&#167;240.14a-12</FONT> </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>Hologic, Inc. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Name of
Registrant as Specified In Its Charter) </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Name of Person(s) Filing Proxy Statement, if other than the Registrant) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Payment of Filing Fee (Check the appropriate box): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9745;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">No fee required </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Fee paid previously with preliminary materials </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules
<FONT STYLE="white-space:nowrap">14a-(6)(i)(1)</FONT> and <FONT STYLE="white-space:nowrap">0-11</FONT> </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;
</DIV><DIV STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>The following contains an email sent to all Hologic, Inc. (&#8220;Hologic&#8221; or the
&#8220;Company&#8221;) employees on October&nbsp;21, 2025. </I></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g54832g1021224525376.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A Message from <B>Steve MacMillan </B> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Chairman, President and CEO </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dear Colleagues, </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">I&#8217;m pleased to share important and exciting news that will position Hologic for an even stronger future and help us build on our mission to enable
healthier lives everywhere, every day. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A few moments ago, we announced that we have agreed to be acquired by Blackstone and TPG for up to $79 per share.
Please see the press release for additional important information. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">I believe this is excellent news for Hologic as a whole, and more specifically for our
employees, customers, patients and stockholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Blackstone and TPG are two of the world&#8217;s most respected investment firms. Each has a long and
successful track record of partnering with innovative healthcare companies to advance their missions and enable growth. They are fully committed to supporting our Purpose, Passion and Promise. They believe we have built a remarkable Company, and
that our people and products play an indispensable role in women&#8217;s health.&nbsp;With their ownership, we will benefit from additional resources, capital and capabilities to improve women&#8217;s health globally and execute on our collective
goals. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We expect our partnership with Blackstone and TPG to mean continued support for our product trajectory and promise for additional growth,
accelerating our pipeline, broadening our international reach and strengthening our capacity for strategic acquisitions. With their deep healthcare expertise and commitment to long-term innovation, Blackstone and TPG will enhance our ability to
deliver critical medical technologies that benefit customers and patients. We will be even better positioned globally, with fewer capital constraints and more opportunities to pursue. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">While this announcement is an important milestone, it is just the first step in a process. The transaction is expected to close in the first half of calendar
year 2026, subject to customary closing conditions, including stockholder and regulatory approvals. Until then, Hologic remains a standalone, publicly listed company, and it is business as usual for all of us. We must remain focused on delivering
the same high-quality products and services to our customers and patients. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We plan to share more information in the coming days, and we look forward to
finding opportunities to introduce you to the Blackstone and TPG teams at the appropriate time. We have spent much time in recent months getting to know them, and we believe firmly that their cultures and approaches are squarely aligned with ours
&#8211; they are excited about the chance to partner with us and work with you. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You likely have questions about what this means for the organization and
you as an employee. Throughout this process, please keep an eye on MyHologic for details. If you interact directly with customers, we will provide you resources to help answer their questions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">I want to thank each of you for your continued dedication and hard work. Today&#8217;s news is a direct reflection of all that we&#8217;ve built together, and
the opportunities ahead will only expand as we move forward with Blackstone and TPG. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Board of Directors, Global Leadership Team and I are incredibly
proud of what we&#8217;ve accomplished, and firmly believe that now is the right time to take Hologic to the next level. We are excited to grow stronger and faster in this next chapter of our journey as we continue to shape the future of
women&#8217;s health globally. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Thank you! </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Steve MacMillan
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Chairman, President&nbsp;&amp; Chief Executive Officer </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Required Legal Disclosures </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Cautionary Statement Regarding Forward-Looking Statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This letter includes &#8220;forward-looking statements&#8221; within the meaning of the &#8220;safe harbor&#8221; provisions of the United States Private
Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;could,&#8221; &#8220;would,&#8221; &#8220;expects,&#8221;
&#8220;plans,&#8221; &#8220;intends,&#8221; &#8220;anticipates,&#8221; &#8220;believes,&#8221; &#8220;estimates,&#8221; &#8220;projects,&#8221; &#8220;predicts,&#8221; &#8220;likely,&#8221; &#8220;future,&#8221; &#8220;strategy,&#8221;
&#8220;potential,&#8221; &#8220;seeks,&#8221; &#8220;goal&#8221;&nbsp;or other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are
not limited to, statements regarding the benefits of and timeline for closing the merger. These&nbsp;forward-looking statements&nbsp;are based upon assumptions made by Hologic as of the date hereof and are subject to known and unknown risks and
uncertainties that could cause actual results to differ materially from those anticipated. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These forward-looking statements are subject to a number of
risks and uncertainties that could adversely affect Hologic&#8217;s business and prospects, and otherwise cause actual results to differ materially from those anticipated, including without limitation, the timing, receipt and terms and conditions of
any required governmental and regulatory approvals of the proposed transaction that could delay the consummation of the proposed transaction or cause the parties to abandon the proposed transaction; the occurrence of any event, change or other
circumstances that could give rise to the termination of the merger agreement entered into in connection with the proposed transaction; the possibility that Hologic stockholders may not approve the proposed transaction; the risk that the parties to
the merger agreement may not be able to satisfy the conditions to the proposed transaction in a timely manner or at all; risks related to disruption of management time from ongoing business operations due to the proposed transaction; the risk that
any announcements relating to the proposed transaction could have adverse effects on the market price of Hologic&#8217;s common stock; the risk of any unexpected costs or expenses resulting from the proposed transaction; the risk of any litigation
relating to the proposed transaction; the risk that the proposed transaction and its announcement could have an adverse effect on the ability of Hologic to retain and hire key personnel and to maintain relationships with customers, vendors,
partners, employees, stockholders and other business relationships and on its operating results and business generally; and the risk that the holders of the CVRs will receive less-than-anticipated payments with respect to the CVRs after the closing
of the proposed transaction. Further information on factors that could cause actual results to differ materially from the results anticipated by the forward-looking statements is included in the Hologic Annual Report on Form <FONT
STYLE="white-space:nowrap">10-K</FONT> for the fiscal year ended September&nbsp;28, 2024<B></B>&nbsp;filed with the Securities and Exchange Commission (the &#8220;<U>SEC</U>&#8221;) on November&nbsp;27, 2024, Quarterly Reports on Form <FONT
STYLE="white-space:nowrap">10-Q,</FONT> Current Reports on Form <FONT STYLE="white-space:nowrap">8-K</FONT> and other filings made by Hologic from time to time with the SEC. These filings, when available, are available on the investor relations
section of the Hologic website at https://investors.hologic.com or on the SEC&#8217;s website at https://www.sec.gov. If any of these risks materialize or any of these assumptions prove incorrect, actual results could differ materially from the
results implied by these forward-looking statements. There may be additional risks that Hologic presently does not know of or that Hologic currently believes are immaterial that could also cause actual results to differ from those contained in the
forward-looking statements. The forward-looking statements included in this letter are made only as of the date hereof. Hologic expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statements
presented herein to reflect any change in expectations or any change in events, conditions or circumstances on which any such statements are based, except as required by law. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Additional Information and Where to Find It </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In
connection with the proposed acquisition of Hologic by affiliates of Blackstone Inc. and TPG Capital, Hologic will file with the SEC a Proxy Statement of Hologic (the &#8220;<U>Proxy Statement</U>&#8221;). Hologic plans to mail to its stockholders a
definitive Proxy Statement in connection with the proposed transaction. HOLOGIC URGES YOU TO READ THE PROXY STATEMENT AND OTHER RELEVANT DOCUMENTS FILED OR TO BE FILED WITH THE SEC CAREFULLY AS THEY BECOME AVAILABLE, AS WELL AS ANY AMENDMENTS OR
SUPPLEMENTS TO THESE DOCUMENTS, BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT HOLOGIC, BLACKSTONE INC., TPG CAPITAL, THE PROPOSED TRANSACTION AND RELATED MATTERS. You will be able to obtain a free copy of the Proxy Statement and other
related documents (when available) filed by Hologic with the SEC at the website maintained by the SEC at www.sec.gov. You also will be able to obtain a free copy of the Proxy Statement and other documents (when available) filed by Hologic with the
SEC by accessing the investor relations section of Hologic&#8217;s website at https://investors.hologic.com or by contacting Hologic investor relations at investors@hologic.com or calling <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">858-410-8904.</FONT></FONT> </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Participants in the Solicitation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Hologic and its directors and executive officers may be deemed to be participants in the solicitation of proxies from Hologic stockholders in connection with
the proposed transaction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Information regarding the directors and executive officers of Hologic, including a description of their direct or indirect
interests, by security holdings or otherwise, is set forth (i)&nbsp;in Hologic&#8217;s definitive proxy statement for its 2025 Annual Meeting of Stockholders, including under the headings &#8220;Proposal No. 1&#8212;Election of Directors,&#8221;
&#8220;Executive Officers,&#8221; &#8220;Compensation Discussion and Analysis,&#8221; &#8220;Executive Compensation Tables,&#8221; &#8220;Securities Ownership by Directors and Executive Officers&#8221; and &#8220;Certain Relationships and
Related-Party Transactions,&#8221; which was filed with the SEC on January&nbsp;16, 2025 and is available at https://www.sec.gov/ix?doc=/Archives/edgar/data/859737/000114036125001287/ny20038205x1_def14a.htm, and (ii)&nbsp;to the extent holdings of
Hologic&#8217;s securities by its directors or executive officers have changed since the amounts set forth in Hologic&#8217;s definitive proxy statement for its 2025 Annual Meeting of Stockholders, such changes have been or will be reflected on
Initial Statement of Beneficial Ownership of Securities on Form 3, Statement of Changes in Beneficial Ownership on Form 4, or Annual Statement of Changes in Beneficial Ownership on Form 5 filed with the SEC, which are available at EDGAR Search
Results https://www.sec.gov/edgar/browse/?CIK=0000859737&amp;owner=only. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Other information regarding the participants in the proxy solicitation and a
description of their direct and indirect interests, by security holdings or otherwise, will be contained in the proxy statement and other relevant materials to be filed with the SEC when they become available. You may obtain free copies of these
documents as described above. </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g54832g1021224525376.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g54832g1021224525376.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $" FP# 2(  A$! Q$!_\0
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MAD?ID9[YI\49(&R/'N>M:=K8R.P)BJ'(TC&Y62V"@DJ"P]6S5F"Q,P+$MCW
MP/TK?M='4@90+D=<5LVNCEE"E-WN#BH<C:-)LY%K%A'M#6SX[%=IJH-/9FV@
MO&_]T=*[N;1ANVQ(7?N!T'U-.BT'+D2(%;_9Z"ESC]D<*NARE\E>HSQ27'AV
MXC!<QL^.=HKTRVT)5 .QL]<]<BK8TE   ,CW&<TO:%>QNCPV2*2$'>NWGY4
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M3#(QIE+0 9)[T44M !0*7BC(H ,4N*;Y@IIE% $F*7BH#+3=[&@5RSN&*3S
M*KC<:<(R: N2^;2&4T@B/I4@A]J!W(M[&CYC5@0>U2K![46 I>633A"35]8/
M:I5@]J ,X6_M3Q;>U:0A'I3Q&*86,];7VJ1;4>E7MHI<"@=BJ+<#M3Q"!4])
M0%A@C [4_:**6D,**,44 %)2TE "4444 )12TE,"0"I%%(!4BTAC@.*0BG#I
M2&D,C(IIJ0TPT@*THXJJPYJY)55AS0 L0YJTM5HQS5I>E #A3J2EI@%%+10
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M[FE+T!<F+TPR>]0EZ:7H%<E,E1F2F%J;DTQ7'ES3":,$TNR@1XOXOT<#Q#>
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M4J]*4B@8S%%+BBF2)333Z2@!E)BGTF*0!2T4M "48I:*!B8IPH%. H 44N*
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M.(W(_NFOG+5R3+(2<G<?YT4542V<U<=ZIG[WXT44V S^+\:DF VP<?Q444T
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>ACN]%%% Q#3#110!"]5V[T44 -C^_5D=*** /__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
